PubRank

T Shirasaka

Author PubWeight™ 57.95‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993 2.27
2 Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987 1.83
3 Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999 1.76
4 Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. J Infect Dis 1995 1.56
5 Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates. J Biol Chem 1995 1.55
6 The MMR question. Lancet 2000 1.42
7 Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 1997 1.35
8 Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gan 1979 1.33
9 In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob Agents Chemother 1993 1.33
10 Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine. Antiviral Res 1995 1.26
11 Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 1998 1.26
12 Effect of uracil on metabolism of 5-fluorouracil in vitro. Gan 1979 1.18
13 In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations. Antimicrob Agents Chemother 1992 1.13
14 Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gan 1978 1.09
15 Monitoring the activity of antiviral therapy for HIV infection using a polymerase chain reaction method coupled with reverse transcription. AIDS 1993 1.07
16 Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999 1.02
17 A C2 symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro. AIDS Res Hum Retroviruses 1994 0.99
18 Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil. Anticancer Res 2001 0.99
19 Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs. J Med Chem 1991 0.93
20 Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity. Eur J Cancer 2003 0.91
21 Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer 1997 0.90
22 Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcomas in rats. Jpn J Cancer Res 1989 0.88
23 Activities of various enzymes of pyrimidine nucleotide and DNA syntheses in normal and neoplastic human tissues. Gan 1982 0.88
24 Escherichia coli mediated biosynthesis and in vitro anti-HIV activity of lipophilic 6-halo-2',3'-dideoxypurine nucleosides. J Med Chem 1991 0.87
25 Studies on a reciprocal relationship between nucleoside kinases and 5'-nucleotidase. Biochim Biophys Acta 1972 0.87
26 Effect of an exogenous energy source and amino acids on DNA synthesis in regenerating rat liver. Biochim Biophys Acta 1983 0.86
27 Moderate neutropenia with S-1 plus low-dose cisplatin may predict a more favourable prognosis in advanced gastric cancer. Clin Oncol (R Coll Radiol) 2006 0.85
28 Metabolism of 5-fluorouracil in various human normal and tumor tissues. Gan 1981 0.85
29 Antitumor activity of BOF-A2, a new 5-fluorouracil derivative. Jpn J Cancer Res 1989 0.85
30 Induction of tumoricidal macrophages from bone marrow cells of normal mice or mice bearing a colony-stimulating-factor-producing tumor. Cancer Immunol Immunother 1989 0.83
31 Feasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer. Oncology 1996 0.83
32 High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy. J Pediatr 1993 0.83
33 Effect of consecutive lower-dose cisplatin in enhancement of 5-fluorouracil cytotoxicity in experimental tumor cells in vivo. Cancer Lett 2000 0.82
34 Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines. J Med Chem 1992 0.82
35 Identification of drug-related genotypic changes in HIV-1 from serum using the selective polymerase chain reaction. Antiviral Res 1994 0.81
36 Metabolism of 5-fluorouracil in sensitive and resistant tumor cells. Gan 1979 0.81
37 Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Cancer Res 1988 0.81
38 [Current status of low-dose CDDP. 5-FU therapy for solid malignant tumors--nationwide questionnaire survey]. Gan To Kagaku Ryoho 1997 0.81
39 In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI. Antiviral Res 1995 0.80
40 In vitro evaluation of experimental agents for anti-HIV activity. Curr Protoc Immunol 2001 0.80
41 Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model. Clin Cancer Res 1999 0.79
42 Crohn's disease associated with selective immunoglobulin a deficiency. J Gastroenterol Hepatol 2001 0.79
43 Metabolism of pyrimidine nucleotides in various tissues and tumor cells from rodents. Gan 1981 0.79
44 Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil. Oncol Rep 1999 0.79
45 Occurrence of autoantibody to protein disulfide isomerase in patients with hepatic disorder. J Toxicol Sci 1994 0.79
46 Quantitative reduction of type I adenylyl cyclase in human alcoholics. Biochim Biophys Acta 1999 0.79
47 [Biochemical modulation of 5-FU--effect of low dose CDDP]. Gan To Kagaku Ryoho 1999 0.79
48 Changes in folate concentration in Yoshida sarcoma after administration of leucovorin or cisplatin. Cancer Chemother Pharmacol 1995 0.78
49 Early onset of drinking and mortality among male alcoholics. A result of a 10-year prospective follow-up study in Hokkaido, Japan. Arukoru Kenkyuto Yakubutsu Ison 1995 0.78
50 Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas. Gan To Kagaku Ryoho 2000 0.78
51 An in vitro examination of a 5-fluorouracil regimen involving continuous venous infusion using cultured cell lines derived from ovarian cancers. Oncol Rep 2000 0.78
52 Continuous infusion of 5-fluorouracil with versus without low-dose, consecutive administration of cisplatin in advanced colorectal cancer. A prospective randomized phase II study. J Exp Clin Cancer Res 2007 0.77
53 [Studies on the mechanism of cytotoxicity of 5-fluorouracil--through impairment of metabolism]. Gan To Kagaku Ryoho 1983 0.77
54 Continuous infusion of 5-fluorouracil plus low-dose cisplatin in tumor-bearing mice. Anticancer Drugs 1997 0.77
55 [Estimation of pathways of 5-fluorouracil anabolism in human cancer cells in vitro and in vivo]. Gan To Kagaku Ryoho 1996 0.77
56 Biochemical modulation therapy for pancreatic cancer. J Hepatobiliary Pancreat Surg 1998 0.77
57 [A comparison of 5-fluorouracil concentration of 5-fluorouracil drip infusion versus orally UFT in plasma of same patients]. Gan To Kagaku Ryoho 1993 0.76
58 Synthesis and antiviral activities of carbocyclic oxetanocin analogues. Chem Pharm Bull (Tokyo) 1990 0.76
59 Efficacy of ecabet sodium enema on steroid resistant or steroid dependent ulcerative colitis. Gut 2006 0.76
60 Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anticancer Drugs 1998 0.76
61 No evidence of persistent mumps virus infection in inflammatory bowel disease. Gut 2001 0.76
62 Participation of arterial baroreceptors input and peripheral vasopressin in the suppression of renal sympathetic nerve activity induced by central salt loading in conscious rats. J Auton Nerv Syst 1999 0.76
63 Syntheses and pharmacological activities of novel optically active inhibitors of acyl-CoA: cholesterol O-acyltransferase: EAB-309 ((R)-N-2-(1,3-benzodioxol-4-yl)heptyl-N'-2,6-diisopropylphenylurea) and its enantiomer. Chem Pharm Bull (Tokyo) 1994 0.76
64 Elevated levels of soluble interleukin-2 receptors in tuberculous pleural effusions. Chest 1990 0.76
65 [Combined chemotherapy with 5-FU and low dose CDDP for advanced or recurrent cancer of the digestive system and home anti-cancer chemotherapy]. Gan To Kagaku Ryoho 1995 0.76
66 Effect of coadministration of thymine or thymidine on the antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gan 1980 0.76
67 Combined effects of S-1, a new form of oral tegafur, plus modulators on ovarian cancer in nude rats. Chemotherapy 1997 0.75
68 [Ambulatory and domiciliary cancer chemotherapy with forearm implant catheter system and low-dose CDDP + 5-FU therapy]. Gan To Kagaku Ryoho 1999 0.75
69 Antiallergic profile of the novel H1-antihistaminic compound levocabastine. Arzneimittelforschung 1993 0.75
70 The number of 5-fluoro-2'-deoxyuridine-5'-monophosphate binding sites and reduced folate pool in human colorectal carcinoma tissues: changes after tegafur and uracil treatment. Cancer Res 1995 0.75
71 Possible regulation of ribonucleoside diphosphate reductase. Gan 1981 0.75
72 [Elevated soluble interleukin-2 receptor and interleukin-2 receptor positive cells in carcinomatous pleural effusions]. Nihon Kyobu Shikkan Gakkai Zasshi 1990 0.75
73 [Combination chemotherapy of continuous infusion 5-FU and daily low-dose CDDP in colorectal carcinoma]. Gan To Kagaku Ryoho 1999 0.75
74 [Low-dose FP therapy for advanced and recurrent gastric cancer]. Gan To Kagaku Ryoho 1999 0.75
75 [Studies of toxohormones and neoplasms]. Nihon Rinsho 1976 0.75
76 Stability of HIV-1 RNA in blood samples from patients with HIV-1 infection as determined by a quantitative polymerase chain reaction-based assay. Clin Diagn Virol 1996 0.75
77 [The clinical effect of chemotherapy with 5-FU and low-dose CDDP in patients with advanced gastric cancer]. Gan To Kagaku Ryoho 1994 0.75
78 Augmentative effect of Nocardia rubra cell-wall skeleton (N-CWS) on lymphokine-activated killer (LAK) cell induction. Cancer Immunol Immunother 1988 0.75
79 [Soluble interleukin-2 receptor levels in patients with pulmonary tuberculosis]. Nihon Kyobu Shikkan Gakkai Zasshi 1989 0.75
80 [Epidemiological studies on tobacco smoking and dependence in Hokkaido prefecture--relation to alcoholism]. Nihon Arukoru Yakubutsu Igakkai Zasshi 1998 0.75
81 [Studies on the mechanism of antitumor activity of 5-FU and its derivatives--relationship between the inhibition of tumor growth and the inhibition of thymidylate synthetase in vivo]. Gan To Kagaku Ryoho 1984 0.75
82 Growth factor from tumor cells. Gan 1982 0.75
83 5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer. Clin Cancer Res 1995 0.75
84 [Development of lipophilic 6-halo-2',3'-dideoxypurine nucleoside and derivatives: approach to develop CNS-targeting anti-HIV agents]. Nihon Rinsho 1993 0.75
85 Synthesis of the optical isomers of 4-[1-(4-tert-butylphenyl)-2-oxo- pyrrolidine-4-yl]methyloxybenzoic acid (S-2) and their biological evaluation as antilipidemic agent. Chem Pharm Bull (Tokyo) 1999 0.75
86 Synergy of Nocardia rubra cell wall skeleton and interleukin 2 in the in vivo induction of murine lymphokine-activated killer cell activity. Jpn J Cancer Res 1989 0.75
87 [Combined effect of S-1 and CDDP as a modulator for colon 26 liver metastasis]. Gan To Kagaku Ryoho 2000 0.75
88 [Clinical manifestation of volatile solvent psychosis]. Nihon Arukoru Yakubutsu Igakkai Zasshi 1997 0.75
89 [Plasma amino acid levels in alcoholics]. Arukoru Kenkyuto Yakubutsu Ison 1993 0.75
90 [CSF neurochemical alterations during alcohol withdrawal]. Arukoru Kenkyuto Yakubutsu Ison 1985 0.75
91 [Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers]. Gan To Kagaku Ryoho 1999 0.75
92 Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer. Gan To Kagaku Ryoho 1995 0.75
93 Synthesis and structure-activity relationships of 2',3'-dideoxypurine nucleosides as potential antiretroviral agents. Nucleic Acids Symp Ser 1991 0.75
94 [Regulation of enzyme activities involved in pyrimidine synthesis and its application to cancer chemotherapy]. Gan To Kagaku Ryoho 1984 0.75
95 [Combination therapy of 5-FU and low dose CDDP for advanced and recurrence gastric cancer]. Gan To Kagaku Ryoho 1995 0.75
96 Augmentation of murine lymphokine-activated killer cell induction by a factor produced by Nocardia rubra cell wall skeleton-stimulated T cells. Jpn J Cancer Res 1989 0.75
97 Characterization of the activity of growth factor from AH-130 tumor cells. Gan 1984 0.75
98 Phosphorylation of smg p21B in rat peritoneal mast cells in association with histamine release inhibition by dibutyryl-cAMP. FEBS Lett 1992 0.75
99 [Innate resistance to thymidylate synthase inhibition after 5-fluorouracil treatment--a rationale of combined use of cisplatin and its optimal administration dose]. Gan To Kagaku Ryoho 1994 0.75
100 The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck. Gan To Kagaku Ryoho 2000 0.75
101 Studies on mitochondrial and microsomal nucleoside diphosphatases of rat liver. J Biochem 1974 0.75
102 Characterization and purification of an immunosuppressive factor produced by a small cell lung cancer cell line. Jpn J Cancer Res 1991 0.75
103 DNA synthesis in tumor-bearing rats: purification of liver thymidine kinase stimulating factor from Yoshida sarcoma. Gan 1980 0.75
104 Pharmacokinetic modulation of plasma 5-fluorouracil concentrations to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil. Jpn J Cancer Res 1989 0.75
105 Soluble interleukin-2 receptors in pulmonary tuberculosis. Jpn J Med 1991 0.75
106 [Reverse transcriptase inhibitors as anti-HIV agents]. Nihon Rinsho 1993 0.75
107 Transplatin, a cisplatin trans-isomer, may enhance the anticancer effect of 5-fluorouracil. J Exp Clin Cancer Res 2006 0.75
108 [Thymidylate synthase inhibition in malignant tumors after oral administration of UFT]. Gan No Rinsho 1986 0.75
109 [Development of fluoropyrimidine derivatives]. Gan To Kagaku Ryoho 1984 0.75
110 [Preliminary clinical evaluation of low-dose CDDP and continuous 5-FU therapy for advanced gallbladder cancer]. Gan To Kagaku Ryoho 2000 0.75
111 Synergistic antitumor effects of BCG and monoclonal antibodies capable of inducing antibody-dependent cell-mediated cytotoxicity. Jpn J Cancer Res 1987 0.75
112 Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 2. 6-Halo and 6-alkoxy prodrugs of 2'-beta-fluoro-2',3'-dideoxyinosine. J Med Chem 1995 0.75
113 [Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma]. Gan To Kagaku Ryoho 1997 0.75
114 [Studies of the antitumor activity and enzymology of 2'-deoxy-5-fluorouridine (FdUrd) derivatives]. Gan No Rinsho 1986 0.75
115 DNA synthesis in tumor-bearing rats. Cancer Res 1975 0.75
116 [Antitumor effect of S-1 and cisplatin treatment against human gastric cancer xenografted in nude mice]. Gan To Kagaku Ryoho 1997 0.75
117 Enhanced inhibition of thymidylate synthase by 5-fluorouracil and [6S]leucovorin combination therapy for breast cancer. Anticancer Res 1994 0.75
118 Enhancement by 2'-deoxycoformycin of the 5'-phosphorylation and anti-human immunodeficiency virus activity of 2',3'-dideoxyadenosine and 2'-beta-fluoro-2',3'-dideoxyadenosine. Mol Pharmacol 1994 0.75
119 [An empirical study on the increase of mild alcoholics in Japan]. Seishin Shinkeigaku Zasshi 1999 0.75